Shanghai Haohai Biological Technology updates on H-share repurchase

Shanghai Haohai Biological Technology Company Limited disclosed its next day disclosure report on November 25, 2025. The report indicates that the company repurchased 93,700 H-shares on November 25, 2025, through the Hong Kong Stock Exchange. The repurchases were executed at prices ranging from HK$27.5 to HK$27.8 per share, totaling HK$2,591,834.

As of November 25, 2025, the company's total issued H-shares (excluding treasury shares) remained unchanged at 38,529,240. The company's total issued A-shares (excluding treasury shares) also remained unchanged at 190,203,760, resulting in a total issued share capital (excluding treasury shares) of 194,051,855 shares.

The company also confirmed that these repurchases were made under a general mandate approved on June 10, 2025, allowing for a maximum repurchase of 3,914,184 shares. As of November 25, 2025, a cumulative total of 1,402,600 shares have been repurchased under this mandate, representing 3.5834% of the shares outstanding at the time of the resolution.